Alpha 2.0
Login Register
» Authors » Ponnusamy Saravanan

Ponnusamy Saravanan

Explore the profile of Ponnusamy Saravanan including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 91
Citations 1572
Followers 0
Related Specialties
Endocrinology
General Medicine
Public Health
Top 10 Co-Authors
Nithya Sukumar
Antonysunil Adaikalakoteswari
Philip G McTernan
Gyanendra Tripathi
Sudhesh Kumar
Hema Venkataraman
Yonas Ghebremichael-Weldeselassie
Vinod Patel
Ranjit Mohan Anjana
Uma Ram
Published In
Nutrients
Clin Med (Lond)
Lancet Diabetes Endocrinol
J Clin Endocrinol Metab
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinical inertia - It is imperative to avoid delays in managing common conditions in pregnancy
Banerjee D, Banerjee A, Saravanan P, Saravanan P
Clin Med (Lond) . 2025 Jan; 25(1):100286. PMID: 39824391
No abstract available.
2.
Infectious diseases at the front door: Focus on the fundamentals
Crocker-Buque T, Saravanan P
Clin Med (Lond) . 2024 Nov; 24(6):100268. PMID: 39613340
No abstract available.
3.
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
Rudofsky G, Amadid H, Braae U, Catrina S, Kick A, Mandavya K, et al.
Diabetes Ther . 2024 Nov; 16(1):73-87. PMID: 39535683
Introduction: Oral semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA) approved for improving glycemic control in adults with type 2 diabetes (T2D). The PIONEER REAL program evaluates clinical and...
4.
PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes
Saravanan P, Bell H, Braae U, Collins E, Deinega A, Dhatariya K, et al.
Adv Ther . 2024 Sep; 41(11):4266-4281. PMID: 39316289
Introduction: Oral semaglutide provides an alternative to injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treatment of type 2 diabetes (T2D). The PIONEER REAL studies evaluate clinical outcomes of oral semaglutide...
5.
Pandemics are here to stay: It's time for unity, both nationally and globally, in how we learn and respond
Saravanan P
Clin Med (Lond) . 2024 Sep; 24(5):100244. PMID: 39307548
No abstract available.
6.
Never forget the basics while seeking correct diagnosis and management
Saravanan P
Clin Med (Lond) . 2024 Aug; 24(4):100232. PMID: 39152031
No abstract available.
7.
Doing simple things well can achieve significant benefits
Saravanan P
Clin Med (Lond) . 2024 Jun; 24(3):100219. PMID: 38937041
No abstract available.
8.
Early pregnancy HbA as the first screening test for gestational diabetes: results from three prospective cohorts
Saravanan P, Deepa M, Ahmed Z, Ram U, Surapaneni T, Kallur S, et al.
Lancet Diabetes Endocrinol . 2024 Jun; 12(8):535-544. PMID: 38936371
Background: More than 90% of gestational diabetes cases are estimated to occur in low-income and middle-income countries (LMICs). Most current guidelines recommend an oral glucose tolerance test (OGTT) at 24-28...
9.
Efficacy and Safety of Trazodone and Gabapentin Fixed-Dose Combination in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Dose-Finding Study
Tesfaye S, Saravanan P, Ehler E, Zinek K, Palka-Kisielowska I, Nastaj M, et al.
Pain Ther . 2024 Jun; 13(4):987-1006. PMID: 38914876
Introduction: Up to 50% of diabetic patients with neuropathy suffer from chronic pain, namely painful diabetic neuropathy (PDN), an unmet medical need with significant impact on quality of life. Gabapentin...
10.
Correction: Prevalence of prediabetes and type 2 diabetes mellitus in south and southeast Asian women with history of gestational diabetes mellitus: Systematic review and meta-analysis
Shivashri C, Hannah W, Deepa M, Ghebremichael-Weldeselassie Y, Anjana R, Uma R, et al.
PLoS One . 2024 May; 19(5):e0304170. PMID: 38753857
[This corrects the article DOI: 10.1371/journal.pone.0278919.].